Tandutinib

Drug Profile

Tandutinib

Alternative Names: CT53518; MLN 518; MLN0518

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Millennium
  • Class Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glioblastoma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 31 Jul 2012 Discontinued - Phase-II for Glioblastoma in USA (PO)
  • 11 May 2012 Phase-II clinical trials in Glioblastoma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top